Event Title
Empowering Therapeutic Peptides by Enhancing its in vivo Half-Life
Loading...
Location
Biology Building, Room 101
Start Date
26-3-2015 6:00 PM
End Date
26-3-2015 7:00 PM
Description
The tremendous therapeutic potential of peptides has not been fulfilled and potential peptide therapies that have failed far outnumber the successes so far. A major challenge impeding the more widespread use of peptides as therapeutics is their poor pharmacokinetic profile, due to short in vivo half-life. Therefore, extending the in vivo half-life of peptides is clearly desirable in order for their therapeutic potential to be realized, without the need for high doses and frequent administration. Our group is developing a novel strategy that will enhance the pharmacokinetic properties of therapeutic peptides, which could decrease dosing frequency and improve patient convenience and compliance.
Empowering Therapeutic Peptides by Enhancing its in vivo Half-Life
Biology Building, Room 101
The tremendous therapeutic potential of peptides has not been fulfilled and potential peptide therapies that have failed far outnumber the successes so far. A major challenge impeding the more widespread use of peptides as therapeutics is their poor pharmacokinetic profile, due to short in vivo half-life. Therefore, extending the in vivo half-life of peptides is clearly desirable in order for their therapeutic potential to be realized, without the need for high doses and frequent administration. Our group is developing a novel strategy that will enhance the pharmacokinetic properties of therapeutic peptides, which could decrease dosing frequency and improve patient convenience and compliance.
Speaker Bio
Dr. Alhamadsheh is an assistant professor in the School of Pharmacy at Pacific. He received his PhD in Organic Chemistry from the University of Toledo and did his postdoctoral studies in Chemical Biology at Stanford University and Portland State University. His research group employs an interdisciplinary approach to studying protein-protein interactions (PPIs), combining organic chemistry with biochemistry and molecular biology. Dr. Alhamdsheh's group is particularly interested in developing chemical tools and therapeutic agents for protein aggregation diseases such as Alzheimer's disease and Transthyretin Amyloidosis. Dr. Alhamadsheh is a recipient of New Investigator Award from AACP. He has co-authored three patents and 17 articles in peer-reviewed journals.